Britain's AstraZeneca is reportedly in discussions to acquire its US rival Bristol Myers Squibb, a move that could create a pharmaceutical giant valued at nearly $400 billion (£300 billion).

The proposed tie-up would represent one of the largest deals in pharmaceutical history, establishing a new entity that would rank as the world's fourth-largest drugmaker by market capitalisation.

The proposed tie-up would represent one of the largest deals in pharmaceutical history.

AstraZeneca, led by its long-serving chief executive Pascal Soriot, is seeking to bolster its drug pipeline and expand its global market reach through the potential acquisition.

Consolidation in the Pharmaceutical Sector

Mega-mergers of this scale are a recurring feature of the pharmaceutical industry, driven by the formidable costs associated with research and development for new medicines.

Companies often pursue such consolidation to overcome patent expiry challenges for established drugs, allowing them to gain new intellectual property and secure a larger market share across diverse therapeutic areas.

Outlook and Regulatory Hurdles

Any definitive agreement would face rigorous scrutiny from regulatory bodies in both the United Kingdom and the United States to assess potential antitrust implications.

Such approval processes for major pharmaceutical deals can often take many months to complete. The successful integration of two such expansive and complex organisations would also present significant operational and cultural challenges for management.

The discussions highlight a continued trend of consolidation within the global pharmaceutical market, as companies seek efficiency and innovation in an increasingly competitive landscape.